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Background
It is known that metachronous colorectal cancer risk for
Lynch syndrome patients with primary colon cancer is
high and total colectomy is the preferred option [1].
However if the index primary cancer is in the rectum,
management advice is complicated by considerations of
worsening bowel function or stoma formation. To aid
surgical decision-making, we estimated the risk of meta-
chronous colon cancer for Lynch syndrome patients
who underwent either anterior resection or abdomino-
perineal resection for primary rectal cancer.
Methods
This retrospective cohort study comprised 79 MMR
gene mutation carriers (18 MLH1,5 5MSH2,4MSH6
and 2 PMS2) from the Colon Cancer Family Registry
who had a surgical resection for their first primary rectal
cancer. Age-dependent cumulative risks of metachro-
nous colon cancer were calculated using the Kaplan-
Meier method. Risk factors for metachronous colon can-
cer were assessed using a Cox proportional hazards
regression.
Results
During 866 person-years of observation (median 9 years;
range 1-32 years) since diagnosis of first rectal cancer, a
total of 21 (27%) carriers were diagnosed with meta-
chronous colon cancer (incidence 24.2; 95% CI 15.8–
37.2 per 1000 person-years). Incidence for carriers who
had an anterior resection (26.8; 95% CI 15.5–46.1 per
1000 person-years) was not different from that for car-
riers who had an abdominoperineal resection (21.0; 95%
CI 10.5–42.1 per 1000 person-years) (P=0.1). Cumula-
tive risk of metachronous colon cancer was 19% (95%
CI 9–31%) at 10 years, 47% (95% CI 31–68%) at 20
years and 69% (95% CI 45–89%) at 30 years after surgi-
cal resection. There was no difference in the frequency
of surveillance colonoscopy between two types of sur-
gery (one colonoscopy per 1.1 (95% CI 0.9–1.2) years
after anterior resection vs. one colonoscopy per 1.4 (95%
CI 1.0–1.8) years after abdominoperineal resection).
Conclusions
For carriers of MMR gene mutations who contract rec-
tal cancer, the metachronous cancer risk is substantial
and mirrors that seen for carriers undergoing segmental
resection for primary colon cancer [1], despite the
majority continuing to receive frequent surveillance
colonoscopy. This risk needs to be considered when the
extent of surgery for primary rectal cancer is planned.
Whereas total colectomy for primary colon cancer in
mutation carriers is appropriate, for primary rectal cases
this strategy has major implications for continence and
need for stoma. Nevertheless, given the high metachro-
nous risk, this needs serious consideration especially for
younger patients.
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